Latest Healthcare It News

WAM Leaders Limited has raised its fully franked full year dividend to 9.4 cents per share despite underperforming the ASX 200 in FY2025, signaling confidence in a market inflection and a strategic pivot towards quality and growth sectors.

WAM Global Limited outperformed the MSCI World Index in FY2025 with a 19.4% portfolio gain, enabling a higher fully franked dividend of 17 cents per share. The company’s strong results reflect strategic investments in undervalued global growth stocks amid volatile markets.

WAM Global Limited reported a robust 39.8% increase in net profit for FY2025, driven by a 19.4% growth in its investment portfolio and declared a fully franked full year dividend of 17 cents per share. The company’s diversified global holdings and disciplined investment approach underpin its strong shareholder returns.

Wellnex Life announces the resignation of joint CEO George Karafotias, with Zack Bozinovski stepping up as sole CEO. The company plans to repay a $705,000 director loan within 90 days.

EMVision Medical Devices has been awarded a $3 million non-dilutive government grant to conduct a pioneering clinical study using its telehealth-enabled emu™ brain scanner in regional South Australia, aiming to transform stroke diagnosis and treatment.

Amcor has completed its transformative acquisition of Berry Global, reporting a 43% jump in quarterly net sales and projecting strong earnings growth for fiscal 2026. The company’s strategic portfolio review and synergy realisation efforts underpin an optimistic outlook.

Cochlear Limited has extended its on-market share buy-back program, allowing the company to repurchase up to AUD 75 million of its fully paid ordinary shares until August 2026.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Cochlear Limited reported a 4% revenue rise in FY25, driven by strong implant sales and launched the world’s first smart cochlear implant system. The company forecasts up to 17% profit growth in FY26, underpinned by innovation and expanding markets.

Cochlear Limited has announced a fully franked ordinary dividend of AUD 2.15 per share for the six months ending June 2025, payable in October with multi-currency options for shareholders.

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

HealthCo Healthcare & Wellness REIT reports FY25 results marked by suspended distributions amid Healthscope receivership, while maintaining strong portfolio fundamentals and active tenant resolution efforts.